[go: up one dir, main page]

WO1996011269B1 - Ligands tie-2, peocedes de production et utilisations de ces ligands - Google Patents

Ligands tie-2, peocedes de production et utilisations de ces ligands

Info

Publication number
WO1996011269B1
WO1996011269B1 PCT/US1995/012935 US9512935W WO9611269B1 WO 1996011269 B1 WO1996011269 B1 WO 1996011269B1 US 9512935 W US9512935 W US 9512935W WO 9611269 B1 WO9611269 B1 WO 9611269B1
Authority
WO
WIPO (PCT)
Prior art keywords
ligand
tie
nucleic acid
receptor
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1995/012935
Other languages
English (en)
Other versions
WO1996011269A9 (fr
WO1996011269A2 (fr
Filing date
Publication date
Priority claimed from US08/319,932 external-priority patent/US5643755A/en
Priority claimed from US08/348,492 external-priority patent/US5879672A/en
Priority claimed from US08/373,579 external-priority patent/US5650490A/en
Priority claimed from US08/418,595 external-priority patent/US5814464A/en
Priority to PL95319586A priority Critical patent/PL184642B1/pl
Priority to US08/817,318 priority patent/US6433143B1/en
Priority to EP95939501A priority patent/EP0784683B1/fr
Priority to CA2202028A priority patent/CA2202028C/fr
Priority to DK95939501T priority patent/DK0784683T3/da
Priority to AT95939501T priority patent/ATE199259T1/de
Priority to CZ19971025A priority patent/CZ292453B6/cs
Priority to JP51267296A priority patent/JP4054375B2/ja
Priority to DE69520149T priority patent/DE69520149T2/de
Priority to NZ296638A priority patent/NZ296638A/xx
Priority to HU9800160A priority patent/HU221422B1/hu
Priority to AU41295/96A priority patent/AU711111B2/en
Priority to ES95939501T priority patent/ES2154354T3/es
Priority to HK98105155.3A priority patent/HK1005944B/xx
Application filed filed Critical
Priority to MX9702530A priority patent/MX9702530A/es
Priority to AT96910769T priority patent/ATE273384T1/de
Priority to DE69633121T priority patent/DE69633121T2/de
Priority to CA2216963A priority patent/CA2216963C/fr
Priority to AU53871/96A priority patent/AU715621B2/en
Priority to PCT/US1996/004806 priority patent/WO1996031598A1/fr
Priority to EP96910769A priority patent/EP0821728B1/fr
Priority to HK98109175.1A priority patent/HK1008230B/en
Priority to JP53053796A priority patent/JP4122056B2/ja
Publication of WO1996011269A2 publication Critical patent/WO1996011269A2/fr
Publication of WO1996011269A9 publication Critical patent/WO1996011269A9/fr
Publication of WO1996011269B1 publication Critical patent/WO1996011269B1/fr
Priority to NO19971557A priority patent/NO322643B1/no
Priority to FI971406A priority patent/FI120313B/fi
Anticipated expiration legal-status Critical
Priority to US09/442,717 priority patent/US6627415B1/en
Priority to GR20010400568T priority patent/GR3035717T3/el
Ceased legal-status Critical Current

Links

Abstract

Cette invention se rapporte à une molécule d'acide nucléique isolée codant un ligand TIE-2 humain. Cette invention se rapporte en outre à un corps récepteur qui fixe spécifiquement un ligand TIE-2 humain, et à un anticorps qui fixe spécifiquement un ligand TIE-2 humain, ainsi qu'à un antagoniste de ligand TIE-2 humain. Cette invention se rapporte également à des compositions thérapeutiques et à un procédé pour bloquer la croissance des vaisseaux sanguins, à un procédé pour promouvoir la néovascularisation, à un procédé pour promouvoir la croissance ou la différenciation d'une cellule exprimant le récepteur de TIE-2, à un procédé pour bloquer la croissance ou la différenciation d'une cellule exprimant le récepteur de TIE-2, ainsi qu'à un procédé pour atténuer ou empêcher la croissance de tumeurs chez l'homme.
PCT/US1995/012935 1994-10-07 1995-10-06 Ligands tie-2, peocedes de production et utilisations de ces ligands Ceased WO1996011269A2 (fr)

Priority Applications (27)

Application Number Priority Date Filing Date Title
MX9702530A MX9702530A (es) 1994-10-07 1995-10-06 Ligandos tie-2, metodos de preparacion y usos de los mismos.
HK98105155.3A HK1005944B (en) 1994-10-07 1995-10-06 Tie-2 ligands, methods of making and uses thereof
ES95939501T ES2154354T3 (es) 1994-10-07 1995-10-06 Ligandos tie-2, metodos para obtenerlos y sus usos.
CZ19971025A CZ292453B6 (cs) 1994-10-07 1995-10-06 Izolovaná molekula nukleové kyseliny kódující TIE-2 ligand a její použití
JP51267296A JP4054375B2 (ja) 1994-10-07 1995-10-06 Ｔｉｅ−２リガンド、その作製方法および使用方法
EP95939501A EP0784683B1 (fr) 1994-10-07 1995-10-06 Ligands tie-2, procedes de production et utilisations de ces ligands
CA2202028A CA2202028C (fr) 1994-10-07 1995-10-06 Ligands tie-2, peocedes de production et utilisations de ces ligands
DK95939501T DK0784683T3 (da) 1994-10-07 1995-10-06 TIE-2-ligander, fremgangsmåder til dannelse af disse og anvendelser deraf
AT95939501T ATE199259T1 (de) 1994-10-07 1995-10-06 Tie-2 ligande, verfahren zu ihrer herstellung, und ihre anwendungen
PL95319586A PL184642B1 (pl) 1994-10-07 1995-10-06 Izolowana czasteczka kwasu nukleinowego kodujaca ligand TIE-2, wektor zawierajacy izolowana czasteczke kwasu nukleinowego, izolowany i oczyszczony ligand TIE-2, uklad gospodarz-wektor, sposób wytwarzania izolowanego i oczyszczonego ligandu TIE-2, przeciwcialo, cialo ligandu, koniugat, kompozycja farmaceutyczna, zastosowanie przeciwciala, zastosowanie izolowanego i oczyszczonego ligandu, sposób in vitro podtrzymywania w hodowli ekspresji receptora TIE-2, sposób identyfikacji antagonisty receptora TIE-2, cialo receptora, izolowana czasteczka kwasu nukleinowego kodujaca cialo receptora, wektor zawierajacy izolowana czasteczke kwasu nukleinowego kodujaca cialo receptora, kompozycja farmaceutyczna zawierajaca cialo receptora PL
US08/817,318 US6433143B1 (en) 1994-10-07 1995-10-06 Tie-2 ligands
DE69520149T DE69520149T2 (de) 1994-10-07 1995-10-06 Tie-2 ligande, verfahren zu ihrer herstellung, und ihre anwendungen
NZ296638A NZ296638A (en) 1994-10-07 1995-10-06 Ligands which bind to tie-2 (tyrosine kinase with ig and egf homology domains) receptors
HU9800160A HU221422B1 (en) 1994-10-07 1995-10-06 Tie-2 ligands, recombinant methods of making and uses thereof
AU41295/96A AU711111B2 (en) 1994-10-07 1995-10-06 Tie-2 ligands, methods of making and uses thereof
PCT/US1996/004806 WO1996031598A1 (fr) 1995-04-06 1996-04-05 Ligands tie-2, procedes d'obtention de ces ligands et leurs utilisations
EP96910769A EP0821728B1 (fr) 1995-04-06 1996-04-05 Ligands tie-2, procedes d'obtention de ces ligands et leurs utilisations
AT96910769T ATE273384T1 (de) 1995-04-06 1996-04-05 Tie-2 liganden, herstellungsverfahren und verwendung
HK98109175.1A HK1008230B (en) 1995-04-06 1996-04-05 Tie-2 ligands, methods of making and uses thereof
JP53053796A JP4122056B2 (ja) 1995-04-06 1996-04-05 Ｔｉｅ−２リガンド、その作製方法および使用方法
DE69633121T DE69633121T2 (de) 1995-04-06 1996-04-05 Tie-2 liganden, herstellungsverfahren und verwendung
CA2216963A CA2216963C (fr) 1995-04-06 1996-04-05 Ligands tie-2, procedes d'obtention de ces ligands et leurs utilisations
AU53871/96A AU715621B2 (en) 1995-04-06 1996-04-05 TIE-2 ligands, methods of making and uses thereof
FI971406A FI120313B (fi) 1994-10-07 1997-04-04 TIE-2-ligandit, niiden valmistusmenetelmät ja käytöt
NO19971557A NO322643B1 (no) 1994-10-07 1997-04-04 Isolert nukleinsyremolekyl som koder for TIE-2-ligand, TIE-2-ligand, fremgangsmate ved fremstilling og anvendelse derav, samt antistoff mot TIE-2-liganden.
US09/442,717 US6627415B1 (en) 1995-04-06 1999-11-18 TIE-2 ligands, methods of making and uses thereof
GR20010400568T GR3035717T3 (en) 1994-10-07 2001-04-06 Tie-2 ligands, methods of making and uses thereof

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US08/319,932 1994-10-07
US08/319,932 US5643755A (en) 1994-10-07 1994-10-07 Nucleic acid encoding tie-2 ligand
US08/330,261 US5521073A (en) 1994-10-07 1994-10-27 TIE-2 ligand, and method of making
US08/330,261 1994-10-27
US08/348,492 US5879672A (en) 1994-10-07 1994-12-02 Tie-2 ligand 1
US08/348,492 1994-12-02
US35350394A 1994-12-09 1994-12-09
US08/353,503 1994-12-09
US08/373,579 1995-01-17
US08/373,579 US5650490A (en) 1994-10-07 1995-01-17 Tie-2 ligand 2
US08/418,595 1995-04-06
US08/418,595 US5814464A (en) 1994-10-07 1995-04-06 Nucleic acids encoding TIE-2 ligand-2

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/418,595 Continuation US5814464A (en) 1994-10-07 1995-04-06 Nucleic acids encoding TIE-2 ligand-2

Related Child Applications (5)

Application Number Title Priority Date Filing Date
US08/817,318 A-371-Of-International US6433143B1 (en) 1994-10-07 1995-10-06 Tie-2 ligands
PCT/US1996/004806 Continuation WO1996031598A1 (fr) 1995-04-06 1996-04-05 Ligands tie-2, procedes d'obtention de ces ligands et leurs utilisations
US10/179,744 Division US20020173627A1 (en) 1999-09-16 2002-06-24 TIE-2 ligands, methods of making and uses thereof
US10/179,615 Division US7063840B2 (en) 1994-10-07 2002-06-24 TIE-2 ligands, methods of making and uses thereof
US10/179,820 Division US20030166858A1 (en) 1999-09-16 2002-06-24 TIE-2 ligands, methods of making and uses thereof

Publications (3)

Publication Number Publication Date
WO1996011269A2 WO1996011269A2 (fr) 1996-04-18
WO1996011269A9 WO1996011269A9 (fr) 1996-06-06
WO1996011269B1 true WO1996011269B1 (fr) 1996-08-22

Family

ID=27559710

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/012935 Ceased WO1996011269A2 (fr) 1994-10-07 1995-10-06 Ligands tie-2, peocedes de production et utilisations de ces ligands

Country Status (22)

Country Link
US (4) US5814464A (fr)
EP (1) EP0784683B1 (fr)
JP (1) JP4054375B2 (fr)
CN (1) CN1230536C (fr)
AT (1) ATE199259T1 (fr)
AU (1) AU711111B2 (fr)
CA (1) CA2202028C (fr)
CZ (1) CZ292453B6 (fr)
DE (1) DE69520149T2 (fr)
DK (1) DK0784683T3 (fr)
ES (1) ES2154354T3 (fr)
FI (1) FI120313B (fr)
GR (1) GR3035717T3 (fr)
HU (1) HU221422B1 (fr)
IL (4) IL115517A (fr)
MX (1) MX9702530A (fr)
NO (1) NO322643B1 (fr)
NZ (1) NZ296638A (fr)
PL (1) PL184642B1 (fr)
PT (1) PT784683E (fr)
WO (1) WO1996011269A2 (fr)
ZA (1) ZA958444B (fr)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681714A (en) * 1992-07-30 1997-10-28 Mount Sinai Hospital Corporation Nucleic acid encoding tek receptor tyrosine kinase
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6245530B1 (en) 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6221839B1 (en) 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
US6130071A (en) * 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
EP0821728B1 (fr) * 1995-04-06 2004-08-11 Regeneron Pharmaceuticals, Inc. Ligands tie-2, procedes d'obtention de ces ligands et leurs utilisations
AU755337B2 (en) * 1995-04-06 2002-12-12 Regeneron Pharmaceuticals, Inc. New uses of tie-2 ligands
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
ES2239338T5 (es) 1995-09-29 2013-05-31 Vegenics Pty Ltd Genes regulados y sus usos
US7063965B2 (en) * 1996-04-05 2006-06-20 Regeneron Pharmaceuticals, Inc. Nucleic acid encoding TIE-2 ligand
DE19623850A1 (de) * 1996-06-14 1997-12-18 Wacker Chemie Gmbh Homogenisierung von Dispersionen
US6846914B2 (en) 1996-06-19 2005-01-25 Regeneron Pharmaceuticals, Inc. Tie-2 ligand-3
IL127623A0 (en) 1996-06-19 1999-10-28 Regeneron Pharma Tie-2 receptor ligands (tie ligand-3; tie ligand-4) and their uses
US5851797A (en) * 1996-06-19 1998-12-22 Regeneron Pharmaceuticals, Inc. Tie ligand-3, methods of making and uses thereof
US6265564B1 (en) * 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule
JP2001517075A (ja) 1996-08-23 2001-10-02 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ 組換え血管内皮細胞増殖因子ｄ（ｖｅｇｆ―ｄ）
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US6057435A (en) * 1997-09-19 2000-05-02 Genentech, Inc. Tie ligand homologues
US6350450B1 (en) 1997-09-19 2002-02-26 Genentech, Inc. TIE ligand homologue antibody
US5972338A (en) 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US6348350B1 (en) 1997-09-19 2002-02-19 Genentech, Inc. Ligand homologues
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
WO1999032515A2 (fr) * 1997-12-19 1999-07-01 Zymogenetics, Inc. Homologue de l'angiopoietine, adn le codant et procede de production dudit homologue
WO1999032639A1 (fr) * 1997-12-19 1999-07-01 Regeneron Pharmaceuticals, Inc. Tyrosine-kinase recepteur, ar-1, regulateur de l'angiogenese
WO1999040193A1 (fr) * 1998-02-04 1999-08-12 Zymogenetics, Inc. Zapo3 homologue d'angiopoietine, adn le codant et sa methode de production
JP2002516067A (ja) * 1998-03-02 2002-06-04 ミレニアム・フアーマシユーチカルズ・インコーポレーテツド 新規ｆｄｒｇタンパク質および核酸分子、ならびにそのための用途
US6479626B1 (en) 1998-03-02 2002-11-12 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
DK1129110T3 (da) 1998-11-10 2010-04-06 Ludwig Inst Cancer Res Blodpladeafledt vækstfaktor D, DNA kodende derfor og anvendelser deraf
WO2000037642A1 (fr) 1998-12-23 2000-06-29 Regeneron Pharmaceuticals, Inc. Technique permettant d'accroitre l'activite biologique de ligands
JP2002537813A (ja) * 1999-03-02 2002-11-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンギオポエチンに関連しているタンパク質および核酸
US6455035B1 (en) 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US6887468B1 (en) 1999-04-28 2005-05-03 Board Of Regents, The University Of Texas System Antibody kits for selectively inhibiting VEGF
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
PT1187918E (pt) 1999-06-07 2006-08-31 Immunex Corp Antagonistas de tek
DE60043367D1 (de) 1999-06-15 2009-12-31 Genentech Inc Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
US6689035B1 (en) 2000-04-11 2004-02-10 Gerber Scientific Products, Inc. Method and apparatus for designing and creating a package
JP2004537260A (ja) 2000-12-07 2004-12-16 サンガモ バイオサイエンシーズ， インコーポレイテッド ジンクフィンガータンパク質による血管新生の調節
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AU2006228095B2 (en) * 2001-10-11 2010-11-04 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2002335085A1 (en) 2001-10-25 2003-05-06 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
JP4242590B2 (ja) * 2002-01-11 2009-03-25 俊一 塩澤 慢性関節リウマチの疾患感受性遺伝子、及びその利用
US7427594B1 (en) * 2002-02-26 2008-09-23 The Trustees Of The University Of Pennsylvania Methods and pharmaceuticals compositions for treating coronary artery disease, ischemia,and vascular disease using angiopoietins
US7081443B2 (en) 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
US20040115640A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of angiopoietin-2 expression
US7479270B2 (en) 2002-07-23 2009-01-20 Vegenics Limited Methods and compositions for activating VEGF-D and VEGF-C
WO2004045531A2 (fr) 2002-11-14 2004-06-03 Cornell Research Foundation, Inc. Protection du myocarge cardiaque
MXPA06000508A (es) 2003-07-18 2006-04-05 Amgen Inc Agentes de union especifica al factor del crecimiento de los hepatocitos.
CN1323723C (zh) * 2003-12-26 2007-07-04 上海新世界基因技术开发有限公司 Tie2受体介导的靶向性肿瘤基因治疗的基因转移系统
US8298532B2 (en) * 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
WO2005087177A2 (fr) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Anticorps chimeriques anti-vegf-d et anticorps humanises anti-vegf-d et leurs procedes d'utilisation
CN101044164A (zh) * 2004-07-20 2007-09-26 健泰科生物技术公司 血管生成素样4蛋白抑制剂，组合，以及其用途
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
PL1838733T3 (pl) 2004-12-21 2012-02-29 Medimmune Ltd Przeciwciała skierowane przeciwko angiopoetynie-2 i ich zastosowania
EP1838321A4 (fr) * 2005-01-07 2009-03-18 Univ Emory Antagonistes de cxcr4 pour le traitement de l'infection due au vih
JP4657757B2 (ja) * 2005-02-23 2011-03-23 株式会社膠原病研究所 肺高血圧症発症関連遺伝子を用いた肺高血圧症の診断および治療
JP2006325528A (ja) * 2005-05-27 2006-12-07 Institute For Rheumatic Diseases Co Ltd 糖尿病性網膜症の診断および予防
JP4657857B2 (ja) * 2005-08-25 2011-03-23 株式会社膠原病研究所 メタボリックシンドロームの診断および予防
BRPI0619853A2 (pt) 2005-12-15 2016-08-23 Astrazeneca Ab combinação, composição farmacêutica, e, métodos de antagonização da atividade biológica, de tratamento de angiogênese relacionada à doença em um mamífero e de tratamento de câncer em um mamífero
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
AU2007251282A1 (en) 2006-05-09 2007-11-22 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
CL2008002444A1 (es) 2007-08-21 2009-09-04 Amgen Inc Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente.
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) * 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
KR101658247B1 (ko) 2008-01-03 2016-09-22 더 스크립스 리서치 인스티튜트 모듈 인식 도메인을 통한 항체 표적화
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
CA2712000A1 (fr) 2008-01-28 2009-08-06 Medimmune Limited Anticorps stabilises contre l'angiopoietine-2 et leurs utilisations
JO2913B1 (en) * 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2009158432A2 (fr) 2008-06-27 2009-12-30 Amgen Inc. Inhibition de l’ang-2 pour traiter la sclérose en plaques
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
KR101431318B1 (ko) * 2009-04-02 2014-08-20 로슈 글리카트 아게 전장 항체 및 단일쇄 ｆａｂ 단편을 포함하는 다중특이성 항체
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8980268B2 (en) 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
US20120189635A1 (en) 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
BR112012005893A2 (pt) 2009-09-16 2016-11-22 Genentech Inc hélice enrolada e/ou complexos de proteínas contendo conectores e usos dos mesmos
WO2011038139A1 (fr) 2009-09-23 2011-03-31 Amgen Inc. Traitement du cancer de l'ovaire au moyen d'un agent de liaison spécifique de l'angiopoïétine-2 humaine en association avec un taxane
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
WO2012009705A1 (fr) 2010-07-15 2012-01-19 Zyngenia, Inc. Complexes liant ang-2 et leurs utilisations
EP2609111B1 (fr) 2010-08-24 2017-11-01 F. Hoffmann-La Roche AG Anticorps bispécifiques comprenand un fv fragment stabilisé au disulfure
WO2012085111A1 (fr) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Complexe polypeptide-polynucléotide et son utilisation dans l'administration d'une fraction effectrice ciblée
KR101638224B1 (ko) 2011-02-28 2016-07-08 에프. 호프만-라 로슈 아게 항원 결합 단백질
KR101572338B1 (ko) 2011-02-28 2015-11-26 에프. 호프만-라 로슈 아게 1가 항원 결합 단백질
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
AU2012275346B2 (en) 2011-06-29 2016-03-17 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
WO2013112438A1 (fr) 2012-01-23 2013-08-01 Regeneron Pharmaceuticals, Inc. Formulations stabilisées contenant des anticorps anti-ang2
BR112014019579A2 (pt) 2012-02-10 2019-10-15 Genentech, Inc Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero
EP2822594A4 (fr) 2012-03-08 2016-02-17 Medimmune Llc Procédés de traitement par des anticorps anti-angiopoïétine-2
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EA031182B1 (ru) 2012-03-30 2018-11-30 Бёрингер Ингельхайм Интернациональ Гмбх Ang2-связывающие молекулы
CN104411718B (zh) 2012-06-27 2018-04-24 弗·哈夫曼-拉罗切有限公司 用于制备包含特异性结合靶的至少一种结合实体的抗体Fc区缀合物的方法及其用途
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
EP2872534B1 (fr) 2012-07-13 2018-08-08 Roche Glycart AG Anticorps bispécifiques anti-ang-2/anti-vegf et leur utilisation dans le traitement des maladies vasculaires oculaires
WO2014108854A1 (fr) 2013-01-09 2014-07-17 Fusimab Ltd. Anticorps anti-hgf et anti-ang2 monospécifiques, et anticorps anti-hgf/anti-ang2 bispécifiques
EP2968541A4 (fr) 2013-03-15 2017-02-08 Zyngenia, Inc. Complexes multispécifiques multivalents et monovalents et leurs utilisations
MX2016003593A (es) 2013-10-11 2016-06-02 Hoffmann La Roche Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico.
AU2014407088B2 (en) 2014-09-26 2021-09-23 Somalogic Operating Co., Inc. Cardiovascular risk event prediction and uses thereof
EP3207059A1 (fr) 2014-10-17 2017-08-23 Amgen Inc. Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 pour thérapies oculaires
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
KR102635212B1 (ko) 2015-03-04 2024-02-13 메조블라스트 인터내셔널 에스에이알엘 중간엽 줄기 세포를 위한 세포 배양 방법
US20190004048A1 (en) 2015-06-26 2019-01-03 Amgen Inc. Biomarker of Survival in the Treatment of Renal Cell Carcinoma with a VEGFR Inhibitor and an Ang2 Inhibitor
DK3389636T3 (da) 2015-12-16 2022-09-19 Regeneron Pharma Sammensætninger og fremgangsmåder til fremstilling af proteinmikropartikler
IL264962B2 (en) 2016-08-23 2024-09-01 Medimmune Ltd Antibodies against VEGF-A and against ANG2 and their uses
KR102586771B1 (ko) 2017-01-30 2023-10-11 리제너론 파마슈티칼스 인코포레이티드 크로마토그래피에서 바이오버든을 감소시키기 위한 조성물 및 방법
EP3694890A4 (fr) 2017-10-12 2021-11-03 Immunowake Inc. Protéine de fusion à chaîne légère d'anticorps vegfr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
WO1995013387A1 (fr) * 1993-11-12 1995-05-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Nouvelle tyrosine-kinase receptrice appelee tie-2
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
AU750414B2 (en) * 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids

Similar Documents

Publication Publication Date Title
WO1996011269B1 (fr) Ligands tie-2, peocedes de production et utilisations de ces ligands
CA2202028A1 (fr) Ligands tie-2, peocedes de production et utilisations de ces ligands
CA2216963A1 (fr) Ligands tie-2, procedes d'obtention de ces ligands et leurs utilisations
RU97107471A (ru) Tie-2 лиганды, способы их получения и применения
JP3600617B2 (ja) ヒト上皮細胞成長因子レセプターに特異的なモノクローナル抗体及びそれを用いた治療剤
US6399068B1 (en) Method of treatment with a non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
JP3589459B2 (ja) 生物応答調節物質の新規な抗体運送システム
AU618722B2 (en) Recombinant pseudomanas exotoxin: construction of an active immunotoxin with low side effects
DE69129421T2 (de) Interleukin 2 enthaltende rekombinante Immunkonjugate für die Therapie
AU631545B2 (en) Il-2 receptor-specific chimeric antibodies
JP3541296B2 (ja) 腫瘍血管内皮細胞に特異的に結合するモノクローナル抗体とその利用方法
EP3444277A1 (fr) Nanocorps anti-pd-l1, séquence de codage et utilisation associées
RU2183215C2 (ru) Конъюгат для стимулирования иммунной реакции против клетки-мишени, способ лечения злокачественных опухолей у млекопитающего
AU6084694A (en) Methods of delivering agents to target cells
Ross et al. Increased Toxicity of Diphtheria Toxin for Human Lymphoblastoid Cells following Covalent Linkage to Anti‐(human lymphocyte) Globulin or Its F (ab′) 2 Fragment
CA2097060A1 (fr) Anticorps bifonctionnels et leur methode de preparation
WO1994009149A1 (fr) Anticorps monoclonal
DE69934903T2 (de) Mitogene regulatoren
WO1989010133A1 (fr) Inhibiteurs de cellules a tiges
AU2002354096B2 (en) Cytotoxic protein and utilization thereof
JPH115749A (ja) 癌治療医薬品組成物
AU673858B2 (en) Monoclonal antibody
CN113321730B (zh) Cldn18.2抗体及其应用
DE69925817T2 (de) Rekombinante onconase und fusionsproteine davon
EP0668923B1 (fr) Anticorps monoclonal